People at Dendright

Helen Roberts (MBA)

Helen is the Chief Executive Officer at Dendright. She has over 13 years industry experience in senior roles with early stage biotechnology companies developing novel technologies in the areas of cancer immunotherapy, nuclear medicine, innate immune modulation and inflammation. In these roles she has managed a diverse range of corporate responsibilities and brings to Dendright broad expertise in program leadership, alliance management, business development, partnering and financing outreach. For 11 years prior to this, Helen held roles of increasing responsibility in global pharmaceutical companies managing multiple marketing teams and new product pipeline portfolios in support of clinical programming, market access strategy and market development. Helen’s qualifications include a science degree in Medical Laboratory Science from QUT and an MBA from University Technology of Sydney.

Professor Ranjeny Thomas (MBBS, FRACP, MD)

Professor Thomas is the Chief Technology Officer and a Director of Dendright. She is also a co-founder of the company and co-inventor on its founding patented technology.

Ranjeny is a clinical rheumatologist with more than 20 years of clinical and scientific experience and is the author of numerous publications on dendritic cell biology, and rheumatoid arthritis. In 2011, she was a plenary speaker at the prestigious American College of Rheumatology Conference in Chicago and a finalist in the Health category of the Australian Innovation Challenge Awards for her research towards a vaccine for RA. Professor Thomas is the Research Leader of the Dendritic Cell Biology Group at the University of Queensland Diamantina Institute situated within the Translational Research Institute, Brisbane Australia.

Dr Craig Belcher (BAppSc, PhD, MBA)

Craig is the Executive Director (Chair) of Dendright. He has considerable experience of the biotechnology industry having done deals in the US, UK and Australia and having worked in Business Development for Cambridge Antibody Technology Limited in the UK for four years before it was acquired by AstraZeneca. Since moving from the UK to UniQuest in 2004, he has closed over 15 deals bringing in over $50 million for R&D at the University of Queensland and raised >$17 million in venture capital for four start-up companies.